Received by email:

File: InMed PR - Board ExpansionI.docx


/
 
 
CSE: IN
OTCQB: IMLFF

Suite 350- 409 Granville ST
Vancouver, BC, Canada V6C-1T2
Tel: 604.669.7207
Email: info@inmedpharma.com
www.inmedpharma.com
 
 


InMed Expands Board of Directors with Senior Life Science and Financial Executives

Appoints Tarek S. Mansour, Ph.D., and Kevin Puil to Board of Directors

Vancouver, BC - March 02, 2015 - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), announced today that T
--->arek Mansour, Ph.D., a veteran executive in the Life Science sector, and Kevin Puil, an experienced investment manager
--->, have joined the company's Board of Directors.  Dr. Mansour has more than 26 years of experience in drug discovery an
--->d development, and has held senior leadership and management positions at leading biotechnology and pharmaceutical com
--->panies.  Mr. Puil is an analyst and former hedge fund manager with 20 years experience managing investments.  These st
--->rategic additions add significant expertise and insight to InMed as the company advances its clinical stage pipeline o
--->f novel therapies.

"We are pleased to welcome Dr. Mansour and Mr. Puil to our Board of Directors," said Craig Schneider, President & CEO.
---> "Dr. Mansour is a distinguished R&D executive and entrepreneur whose experience and expertise in both biotechnology a
--->nd pharmaceutical drug development will be instrumental in guiding our strategic initiatives.  As we continue along ou
--->r accelerated growth trajectory, Mr. Puil's expertise in finance and investments significantly strengthens InMed's inf
--->rastructure.  We look forward to leveraging their collective insight as we move forward."

Dr. Mansour was previously with Xenon Pharmaceuticals as their Executive Vice-President. He also held similar position
--->s at Pfizer and Wyeth Pharmaceuticals prior to founding Sabila Biosciences LLC, where he is currently the Chief Execut
--->ive Officer.

Dr. Mansour's expertise spans multiple therapeutic areas including anti-infectives, oncology, inflammatory, metabolic,
---> cardiovascular and pain. Under his leadership, several compounds have progressed to various stages of clinical evalua
--->tion including FDA approvals and late stage development. Amongst these candidates are Epivir, Zeffix, Troxatyl, Bosuli
--->f, Neratinib and PFE384.

Dr. Mansour received a B.S. degree in Chemistry from the American University of Beirut, Lebanon (1977), M.Sc. in Chemi
--->stry from the University of Manchester Institute of Science and Technology, U.K. (1979), a Ph.D. degree from the Unive
--->rsity of Missouri-Columbia, U.S.A. (1982) and a diploma in Applied Management from McGill University, Canada (1993). F
--->ollowing postdoctoral tenure at the University of Ottawa, Dr. Mansour moved to McGill University in 1985 as a research
---> associate in the Immunomedicinal Chemistry Chair.

Mr. Puil is currently a Managing Partner at a Private Equity fund based in California. Prior to that, he held senior p
--->ositions at several firms including Bolder Investment Partners in Vancouver (now Haywood Securities), where he was a P
--->artner and Portfolio Manager; and in San Francisco at Gissen & Associates as Portfolio Manager and the Encompass Fund 
--->as Senior Analyst. Kevin currently serves as a Board Director of two Toronto Stock Exchange companies. He holds a degr
--->ee in Economics from the University of Victoria in British Columbia, and is a Chartered Financial Analyst (CFA) charte
--->rholder. 


About InMed 
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the researc
--->h and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed
--->'s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value dri
--->vers of the company. For more information, visit www.inmedpharma.com

ON BEHALF OF THE BOARD

InMed Pharmaceuticals Inc.
Craig Schneider     
President and Chief Executive Officer    
T: 604.669.7207
F: 604.683.2506
E: info@inmedpharma.com

Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. (Investors)
jdrumm@tiberend.com
212-375-2664
Amy Wheeler (Media)
awheeler@tiberend.com
646-362-5750

Forward Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-look
--->ing information") within the meaning of applicable securities laws.  Forward-looking information is based on managemen
--->t's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual res
--->ults to differ materially from those described in the forward-looking statements.  Forward-looking information in this
---> news release includes statements about the use of net proceeds from the private placement and the expected fundamenta
--->l value drivers of the company. Although such statements are based on management's reasonable assumptions, there can b
--->e no assurance that such assumptions will prove to be correct.  Such statements involve known and unknown risks, uncer
--->tainties and other factors that may cause actual results, performance or achievements to be materially different from 
--->those implied by such statements. Known risk factors include, among others: InMed may not use net proceeds received fr
--->om the private placement as currently contemplated and InMed's proprietary platform technology, product pipeline and a
--->ccelerated development pathway may not return their expected level of value. 

A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's continuous disclosure f
--->ilings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qua
--->lified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such f
--->orward-looking information or to publicly announce the result of any revisions to any of the forward-looking informati
--->on contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY 
--->FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.